GT200100238AA - Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238) - Google Patents
Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238)Info
- Publication number
- GT200100238AA GT200100238AA GT200100238AK GT200100238K GT200100238AA GT 200100238A A GT200100238A A GT 200100238AA GT 200100238A K GT200100238A K GT 200100238AK GT 200100238 K GT200100238 K GT 200100238K GT 200100238A A GT200100238A A GT 200100238AA
- Authority
- GT
- Guatemala
- Prior art keywords
- osteoporosis
- fractionary
- lapi
- receptor
- derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25327500P | 2000-11-27 | 2000-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200100238AA true GT200100238AA (es) | 2004-05-12 |
Family
ID=22959588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200100238AK GT200100238AA (es) | 2000-11-27 | 2001-11-27 | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238) |
| GT200100238A GT200100238A (es) | 2000-11-27 | 2001-11-27 | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200100238A GT200100238A (es) | 2000-11-27 | 2001-11-27 | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. |
Country Status (41)
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK5562003A3 (en) * | 2000-11-27 | 2004-08-03 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
| KR20040015364A (ko) * | 2001-07-16 | 2004-02-18 | 에프. 호프만-라 로슈 아게 | Ｅｐ4 수용체 작용물질로서의 프로스타글란딘 유사체 |
| DK1408961T3 (da) * | 2001-07-16 | 2007-11-05 | Hoffmann La Roche | 2 pyrrolidon-derivater som prostanoide agonister |
| IL159996A0 (en) * | 2001-07-23 | 2004-06-20 | Ono Pharmaceutical Co | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| WO2003074483A1 (fr) | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
| EP1490055A1 (en) * | 2002-03-18 | 2004-12-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| BR0308738A (pt) * | 2002-03-18 | 2005-01-11 | ||
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| WO2003103604A2 (en) * | 2002-06-01 | 2003-12-18 | Applied Research Systems Ars Holding N.V | Gamma lactams as prostaglandin agonists and use thereof |
| JP2005534653A (ja) * | 2002-06-06 | 2005-11-17 | メルク フロスト カナダ アンド カンパニー | 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体 |
| AU2003233729B2 (en) * | 2002-06-06 | 2007-10-04 | Merck Frosst Canada Ltd | 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma |
| GB0219143D0 (en) * | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| AU2003275838A1 (en) * | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
| JP2006510742A (ja) | 2002-11-08 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼科組成物 |
| US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| CN1735597A (zh) * | 2003-01-10 | 2006-02-15 | 霍夫曼-拉罗奇有限公司 | 作为前列腺素激动剂的2－哌啶酮衍生物 |
| WO2004065365A1 (ja) * | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| CA2513652A1 (en) | 2003-03-03 | 2004-09-16 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
| US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| JP2006528154A (ja) | 2003-07-18 | 2006-12-14 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | プロスタグランジン受容体のモジュレータとしてのヒドラジド誘導体 |
| US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
| JP2007504228A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼組成物 |
| WO2005026128A1 (en) | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| EP1663221A4 (en) | 2003-09-04 | 2009-04-22 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| WO2005060946A1 (en) * | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass |
| US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| JP2008507521A (ja) | 2004-07-20 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科用組成物 |
| JP4893999B2 (ja) | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
| JP2008518013A (ja) * | 2004-10-26 | 2008-05-29 | アラーガン、インコーポレイテッド | プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 |
| WO2006052630A1 (en) * | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
| AU2005304764B2 (en) * | 2004-11-08 | 2012-07-12 | Allergan, Inc. | Substituted pyrrolidone compounds as EP4 agonists |
| US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| WO2006080323A1 (ja) * | 2005-01-27 | 2006-08-03 | Asahi Kasei Pharma Corporation | ヘテロ６員環化合物及びその用途 |
| ATE515263T1 (de) * | 2005-05-06 | 2011-07-15 | Allergan Inc | Substituierte beta-lactame und deren verwendung in der medizin |
| US7772392B2 (en) | 2005-05-06 | 2010-08-10 | Allergan, Inc. | Therapeutic substituted β-lactams |
| US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| KR100598678B1 (ko) * | 2006-02-15 | 2006-07-19 | (주)아이앤씨 | 수직형 대형 폐기물 파쇄기 |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| EP2120962A1 (en) | 2006-12-18 | 2009-11-25 | Allergan, Inc. | Methods and compositions for treating gastrointestinal disorders |
| CN101686985A (zh) | 2007-05-08 | 2010-03-31 | 国立大学法人浜松医科大学 | 含有ep4激动剂的细胞毒性t细胞的活化剂 |
| PL2155733T3 (pl) * | 2007-05-23 | 2013-02-28 | Allergan Inc | Cykliczne laktamy do leczenia jaskry lub podwyższonego ciśnienia śródgałkowego |
| US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
| US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
| US7705001B2 (en) * | 2008-03-18 | 2010-04-27 | Allergan, Inc | Therapeutic substituted gamma lactams |
| CA2733247C (en) * | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| WO2011047048A1 (en) | 2009-10-14 | 2011-04-21 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| DK2545917T3 (en) * | 2010-03-08 | 2016-11-14 | Kaken Pharma Co Ltd | NEW EP4 AGONIST. |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| EP2397141A1 (en) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2678022A2 (en) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814482A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814526B1 (en) | 2012-02-16 | 2016-11-02 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2014015247A1 (en) * | 2012-07-19 | 2014-01-23 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| US20150272874A1 (en) | 2012-10-29 | 2015-10-01 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| EP3235817B1 (en) * | 2013-03-15 | 2018-12-12 | Cayman Chemical Company, Incorporated | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| AU2014229065B2 (en) | 2013-03-15 | 2017-03-09 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
| US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| AU2014290512A1 (en) * | 2013-07-19 | 2015-11-12 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
| JP6694385B2 (ja) | 2013-08-09 | 2020-05-13 | アーデリクス，インコーポレーテッド | リン酸塩輸送阻害のための化合物及び方法 |
| WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
| WO2015188152A1 (en) | 2014-06-06 | 2015-12-10 | Allergan, Inc. | Novel ep4 agonists as therapeutic compounds |
| US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
| CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
| CN107011377B (zh) * | 2017-05-03 | 2019-02-26 | 南通书创药业科技有限公司 | 一种β-羰基磷酸酯的制备方法 |
| AU2018396402C1 (en) | 2017-12-25 | 2021-03-18 | Asahi Kasei Pharma Corporation | Nitrogen-containing 6-membered cyclic compound |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1158163A (en) | 1966-06-15 | 1969-07-16 | Berk Ltd | Improvements in or relating to Polymer Compositions |
| ZA72645B (en) * | 1971-03-05 | 1972-11-29 | Upjohn Co | Prostaglandin analogs |
| DE2346706A1 (de) * | 1973-09-17 | 1975-04-03 | Hoechst Ag | Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung |
| US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
| US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
| NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
| DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| SE423813B (sv) * | 1976-08-06 | 1982-06-07 | Pfizer | Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper |
| US4177346A (en) * | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| US4320136A (en) * | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
| US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
| TW288010B (pt) | 1992-03-05 | 1996-10-11 | Pfizer | |
| SE9302334D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
| ZA944647B (en) | 1993-07-06 | 1995-01-06 | Astra Ab | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives |
| TW420669B (en) | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
| US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
| US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
| EP1121133A1 (en) * | 1998-10-15 | 2001-08-08 | Merck & Co., Inc. | Methods for stimulating bone formation |
| AU1444200A (en) | 1998-10-15 | 2000-05-01 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
| WO2001046140A1 (en) * | 1999-12-22 | 2001-06-28 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
| ATE327751T1 (de) * | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| SK5562003A3 (en) * | 2000-11-27 | 2004-08-03 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
2001
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en active IP Right Grant
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 EP EP01978757A patent/EP1339678B1/en not_active Expired - Lifetime
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
-
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
-
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200100238AA (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238) | |
| CR6678A (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis | |
| CO4910163A1 (es) | Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas | |
| BR0308208A (pt) | Composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, métodos para inibir a atividade de catepsina em um mamìfero que disto necessita, para tratar ou prevenir uma doença, para tratar condições dependentes de catepsina em um mamìfero que disto necessita, para inibir ressorção óssea, para incrementar a densidade mineral óssea, e, para reduzir o risco de fraturas | |
| BR0211364A (pt) | Composição farmacêutica para tratamento de doenças associadas com redução na massa óssea compreendendo o agonista ep4 como componente ativo | |
| BR0100381A (pt) | Tratamento de osteoporose com agonistasseletivos do receptor ep/2/ep4 | |
| BRPI0513491A (pt) | composições inseticidas com base em inseticidas e saffeners selecionados | |
| AR060409A1 (es) | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja y la terapia combinada relacionada a estos agonistas | |
| BR0111210A (pt) | Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias | |
| PA8452701A1 (es) | Agonistas de prostaglandinas | |
| BR0310087A (pt) | Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas | |
| AR040695A1 (es) | Polipeptido de lactoferrina para mejorar la salud osea | |
| DE60225143D1 (de) | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes | |
| BRPI0417416A (pt) | composição de confeitaria de branqueamento de dentes oral sólida | |
| BR0203267A (pt) | Combinações farmacêuticas para o tratamento de doenças neurodegenerativas | |
| AU2003251728A8 (en) | Placental growth factor as a target for the treatment of osteoporosis | |
| CR6952A (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis | |
| GB0422929D0 (en) | Bioactive vitamin D analogues | |
| IL156639A0 (en) | Phenethanolamine derivatives, methods for their preparation and pharmaceutical compositions containing them | |
| ECSP972347A (es) | Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas | |
| GT199800084A (es) | Derivados dipeptidicos. | |
| UY26651A1 (es) | Terapia combinada para la osteoporosis | |
| ECSP982554A (es) | Agonistas de prostaglandinas | |
| AR019492A1 (es) | COMPOSICIONES FARMACÉUTICAS DE LIBERACIoN CONTROLADA |